secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028522
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q2 cash $0.3M, net loss widens to $6.6M; Phase 3 adult ADHD trial misses primary endpoint
--------------------------------------------------------------------------------

- Cash and equivalents $0.3M at June 30, 2023; expects to fund operations only into September 2023.
- Net loss $6.6M in Q2 2023 vs $4.0M in Q2 2022; R&D expenses $4.5M vs $2.2M.
- Phase 3 adult efficacy trial of CTx-1301 did not achieve statistical significance on primary endpoint; effect size 1.79 cited.
- Private placement with WFIA: 1,823,155 shares at $0.5485, gross proceeds $1.0M, closed August 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/0001493152-23-028522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer